Clinical Trials · NCT00003283

Octreotide With or Without Prednisone in Treating Patients With Metastatic or Recurrent Thymoma

CompletedPhase 2Octreotide (Approved)
Phase
Phase 2
Recruitment status
Completed
Sponsor
Eastern Cooperative Oncology Group
Enrollment
38
Start date
Oct 1998
Locations
25 sites, United States, South Africa
Primary endpoint
Study in Thymoma and Thymic Carcinoma
View Octreotide compound reference